Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for PFIZER

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 21, 2025

Official filing document

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 6
Health Issues

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN.

Taxation/Internal Revenue Code

Tax issues affecting the pharmaceutical industry including international tax; including tax issues under consideration for reconciliation legislation and H.R. 1, One Big Beautiful Bill Act". Vaccine excise tax issues and VICP.

Medicare/Medicaid

Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Trade (domestic/foreign)

Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.

Budget/Appropriations

Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access.

Defense

Issues related to pharmaceutical manufacturing and development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem